Since a chance for cure was found out in metastatic colorectal cancer (mCRC)patients undergoing a resection of liver and lung metastases, high tumorshrinkage by chemotherapy regimens and their combination with targetedagents have been addressed in potentially resectable mCRC. However, mostmCRC patients cannot reach this opportunity because of tumor burden ormetastatic sites. For these patients a salvage systemic therapy could be offeredto prolong survival. To date, a huge number of clinical trials provided someevidences for the achievement of this goal. A lot of chemotherapeutic regimensin combination with biological therapies are now available. We triedto propose a simple way to choose the best options and to plan an optimalsequence of treatments. This tool could help the oncologists worldwide tobetter and easily manage mCRC patients who need salvage systemic therapy.
|Numero di pagine||6|
|Rivista||Expert Opinion on Biological Therapy|
|Stato di pubblicazione||Published - 2014|
All Science Journal Classification (ASJC) codes
- Drug Discovery
- Clinical Biochemistry